Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In “Molecular Therapy,” a team led by Armin Rehm at the Max Delbrück Center presents an improved immunotherapy that recognizes two distinct features of malignant cells to destroy the cancer more effectively.

New preclinical research suggests that bowel preparation procedures for colonoscopies may temporarily alter gut balance, culminating in unappreciated effects in patients with compromised gastrointestinal health.

City of Hope®, a leading cancer research and treatment organization, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announce a collaboration focused on the City of Hope-developed IL13RA2-EGFR CAR T cell program addressing glioblastoma multiforme. City of Hope licensed this technology to Mustang Bio Inc. Under the collaboration, City of Hope will evaluate Cellares’ Cell Shuttle™ automated manufacturing platform and Cell Q™ automated quality control system to enable reliable, high-throughput manufacturing and quality control of its CARpool program. By engaging at the preclinical stage, the collaboration will establish platform processes and analytics purpose-built for solid tumor CAR T programs, accelerating advancement into clinical trials while enabling scalable manufacturing to meet global patient demand.

The partnership enables Fox Chase to become the first NCI-designated Comprehensive Cancer Center to implement clinical testing utilizing Arima's 3D-genomics technology in multiple tumor types as part of a standard protocol.

The Krainer lab discovered a three-oncogene circuit that helps drive the aggressive progression of pancreatic ductal adenocarcinoma. Using antisense oligonucleotide technology, the team developed a potential RNA therapy. In lab tests, the new treatment broke the cancerous circuit, reduced tumor viability, and triggered a type of programmed cell death.

Researchers at the University of Southampton have developed a promising new way to bolster the body’s immune system response to cancer.

In a study published in Nature Communications, researchers used specially engineered multi-pronged antibodies to better activate cancer-killing T cells.

The antibodies work by ‘grabbing’ and ‘clustering’ multiple immune cell receptors – boosting the signal which tells the T cell to attack the cancer.